BostonGene

BostonGene's whole transcriptome sequencing (WTS / RNA-seq) of nearly 20,000 genes enables precise identification of gene fusions, expression levels, and gene expression signatures in a CLIA/CAP environment.

CLIA-certified and CAP-accredited whole transcriptome sequencing platform used for precise patient identification in clinical trials.

Cancer immunohistochemistry assays for protein expression evaluation in solid tumors and hematological malignancies.

Testing for clinically actionable biomarkers such as PD-L1 & MMR.

Interrogates a proprietary whole exome and whole transcriptome sequencing database for comprehensive genomic profiling of single nucleotide variants, copy number alterations, insertions/deletions and fusions.

Mines a proprietary pan-cancer database of over 100,000 transcriptomic profiles for drug target expression data to optimize drug development strategies.

Cellular heterogeneity analysis using the single-cell RNA-seq service provides insight into gene expression at the individual cell level.

Single-cell RNA sequencing analysis for tumor microenvironment profiling and cellular heterogeneity analysis.

AI-based pathology platform detects and characterizes tissue composition including tumor, stroma, fibrosis, fat, and necrosis, enabling high-throughput analysis of 100 slides in 20 minutes.

H&E histological analysis enables precise identification of a tissue’s structures, allowing accurate diagnosis and characterization of pathological changes in tissue samples.

State-of-the-art flow cytometry solutions to assess immune system status from a standard blood sample.

Cellular immunoprofiling using high-resolution flow cytometry provides an in-depth analysis of cellular populations and immune responses, enabling a detailed understanding of disease states and therapeutic targets.

Detecting minimal residual disease (MRD) with high sensitivity and specificity using flow cytometry improves disease monitoring and helps personalize cancer treatment options.

Custom fluorescence-activated cell sorting (FACS) and sequencing solutions enable precise isolation and analysis of target cell populations.

Magnetic cell enrichment strategies allow isolation of target cell populations for downstream applications, including functional analysis.

Integrated multiomics solutions and analytical modules to understand a complex disease, combining molecular diagnostics with tailormade analytics.

A machine-learning and NCCN Guidelines-based component of the BostonGene Tumor Portrait test that determines appropriate procedures, treatments, and diagnostic tests based on a patient's unique biological and clinical profile.

An advanced DNA and RNA profiling test that utilizes AI-powered analysis to determine the origin of tumors in patients with cancer of unknown primary or uncertain diagnosis.

An end-to-end AI platform that integrates advanced bioinformatics, next-generation sequencing, flow cytometry, and imaging technologies for comprehensive molecular and cellular tumor profiling.

An analytical platform for tumor microenvironment analysis that classifies patient tumors into 4 distinct tumor microenvironment types from RNA-seq data to guide immunotherapy treatment strategy and predict prognosis.

A proprietary algorithm component of the BostonGene Tumor Portrait test that estimates cancer prognosis by analyzing functional gene expression signatures.

A comprehensive examination of the ctDNA fraction to identify clinically relevant gene alterations, monitor treatment response, and detect residual disease.

Advanced analysis of RNA transcripts released into circulation by tumor cells and other diseased tissues unlocks comprehensive insights into disease states and treatment responses.

BostonGene's immune system profiling assay provides a comprehensive snapshot of the patient's global immune system using a single tube of blood, combining flow cytometry with whole transcriptome sequencing.

WES analysis identifies disease-related genetic alterations, providing molecular profile of the disease that can be used to develop personalized treatment options.

Comprehensive molecular and functional tumor microenvironment profiling for pan-solid tumors based on transcriptomic data and manually curated gene expression signatures.

AI-based algorithm accurately detects the expression of target biomarkers in both tumor and immune cells across various nuclear, cytoplasmic, membrane, and ADC markers.

ctDNA analysis provides detection of clinically relevant gene alterations for disease progression and treatment response monitoring and is easily integrated with BostonGene’s WES mutation calling pipeline.

A unique machine learning cellular deconvolution algorithm trained on artificial transcriptomes to accurately reconstruct the tumor microenvironment using bulk RNA-seq.

A transcriptome-driven exploratory engine applied to cfRNA analysis to investigate tumor characteristics and transcriptional programs from a standard blood sample.

Immune repertoire sequencing from FFPE samples delivers an immune system analysis with data that has comparable quality to analysis performed with fresh tissue.

Immunohistochemistry (IHC) service provides solutions for a wide range of quantitative image analysis requirements featuring high-resolution imaging and accurate detection of specific IHC biomarkers in tissue samples.

PD-L1 testing recommended for selecting patients for Keytruda and Libtayo treatment with primary scoring systems including TPS and CPS.

TCR/BCR-seq provides information on immune repertoire diversity and functionality.

An end-to-end multiplex immunofluorescence (MxIF) pipeline offering a comprehensive overview of tissue architecture and cell-cell interactions by detecting up to 40 protein markers from a single slide.

BostonGene's AI-based digital pathology platform identifies distinct characteristics of the tumor and microenvironment, significantly reducing manual analysis and minimizing variability.

An ML-based tool that differentiates the expression of tumor and tumor microenvironment (TME) cells from bulk RNA-seq samples.

Comprehensive flow cytometry panel offering including 4 panels for B-, T-, NK- cells, monocytes, DC and ILC with 78 unique markers including intracellular markers.

Mismatch repair testing for four key MMR proteins recommended for patients with solid tumors being considered for immunotherapy.

Slide scanner and staining system used to acquire images and perform high throughput staining.

Flow cytometry panel offering including 10 panels for B-, T-, NK- cells, monocytes and DC with 61 unique markers.

Flow cytometry panel featuring a Bone Marrow Multiple Myeloma Panel with 25 unique markers and ~9 cell populations.

Automated fluid control system for cyclic imaging and deep tissue characterization.